We have a successful track record of operating a robust B2B model, catering to the diverse injectable needs of global pharmaceutical companies. Our B2B model covers IP-led, technology transfer and contract manufacturing models. In addition, our B2C model is largely focused on Indian markets, where our products are primarily marketed and sold to end-consumers, such as hospitals, nursing homes and government facilities.
We value our ability to constantly deliver high-quality products. We have established our credentials as a reliable injectable development and manufacturing company. We ensure a steady supply of affordable and quality medicine, with a commitment to make a difference in the peoples’ lives. Over the years, we have made substantial investments in our manufacturing infrastructure to support our product portfolio. We have also significantly improved our R&D capabilities to consistently deliver sterile injectables and ophthalmic products. At present, we have eight manufacturing facilities – consisting of four formulation and four API facilities.
Finished Formulation Facilities